A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma

Blood Adv. 2022 Sep 27;6(18):5262-5266. doi: 10.1182/bloodadvances.2021006555.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adenine / analogs & derivatives
  • Humans
  • Lymphoma, Mantle-Cell* / drug therapy
  • Lymphoma, Mantle-Cell* / pathology
  • Neoplasm Recurrence, Local* / drug therapy
  • Piperidines / therapeutic use
  • Pyrimidines / therapeutic use
  • Quinazolines / therapeutic use

Substances

  • Piperidines
  • Pyrimidines
  • Quinazolines
  • ibrutinib
  • Adenine
  • copanlisib